Immunotherapy and Innovative Therapeutics Unit, Medical Oncology and Hematology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Immunotherapy and Innovative Therapeutics Unit, Medical Oncology and Hematology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
ESMO Open. 2021 Feb;6(1):100046. doi: 10.1016/j.esmoop.2020.100046. Epub 2021 Jan 25.
In the landscape of cancer immunotherapy, immune cell engagers (ICEs) are rapidly emerging as a feasible and easy-to-deliver alternative to adoptive cell therapy for the antitumor redirection of immune effector cells. Even if in hematological malignancies this class of new therapeutics already hit the clinic, the development of ICEs in solid tumors still represents a challenge. Considering that ICEs are a rapidly expanding biotechnology in cancer therapy, we designed this review as a primer for clinicians, focusing on the major obstacles for the clinical implementation and the most translatable approaches proposed to overcome the limitations in solid tumors.
在癌症免疫疗法领域，免疫细胞接合器（ICEs）作为一种可行且易于实施的替代方案，正在迅速取代过继细胞疗法，用于免疫效应细胞的抗肿瘤重定向。尽管在血液恶性肿瘤中，这类新型治疗药物已经进入临床应用，但 ICEs 在实体瘤中的开发仍然是一个挑战。鉴于 ICEs 是癌症治疗中一个迅速发展的生物技术，我们将这篇综述设计为临床医生的入门读物，重点介绍了临床实施的主要障碍，以及为克服实体瘤局限性而提出的最具转化潜力的方法。
